Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients.
Fish oil has been recently proposed as a possible effective treatment in inflammatory bowel disease (IBD); however, a lot of annoying side effects (ie, belching, halitosis, diarrhea, etc) affect patient compliance. We carried out a study of patient tolerance in a group of Crohn's disease (CD) patients with a new fish oil derivative consisting of 500-mg capsules of eicosapentaenoic-docosahexaenoic (EPA 40%-DHA 20%), a free fatty acid mixture (Purepa), and we also evaluated its incorporation into phospholipids, both in plasma and in red cell membranes. Five groups of 10 CD patients in remission received nine Purepa capsules daily in four different preparations (A: uncoated, B: coated, pH 5.5; C: coated, pH 5.5, 60 min time release; D: coated, pH 6.9) and 12 x 1-g capsules daily of a triglyceride preparation (Max-EPA, EPA 18%-DHA 10%), respectively. We coated three of the four Purepa preparations in order to delay the release of contents in an attempt to minimize the side effects. After six weeks of treatment, the group taking Purepa capsules, coated, pH 5.5, 60 min time release (group C) showed the best incorporation of EPA and DHA in red blood cell phospholipid membranes (EPA from 0.2 to 4.4%, DHA from 3.7 to 6.3%), and no side effects were registered, whereas in all other groups side effects were experienced in 50% or more of subjects. This new preparation will make it possible to treat patients for long periods.
Belluzzi
A
A
Istituto di Clinica Medica e Gastroenterologia, Cattedra di Medicina, d'Urgenza, Servizio di Farmacologia Clinica, Bologna, Italy.
Brignola
C
C
Campieri
M
M
Camporesi
E P
EP
Gionchetti
P
P
Rizzello
F
F
Belloli
C
C
De Simone
G
G
Boschi
S
S
Miglioli
M
M
D000328:Adult; D003424:Crohn Disease / Q000178:diet therapy* / Q000378:metabolism; D003692:Delayed-Action Preparations; D004042:Dietary Fats, Unsaturated / Q000009:adverse effects / Q000627:therapeutic use*; D004281:Docosahexaenoic Acids; D004338:Drug Combinations; D015118:Eicosapentaenoic Acid; D004910:Erythrocyte Membrane / Q000378:metabolism; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D005260:Female; D005395:Fish Oils / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008563:Membrane Lipids / Q000378:metabolism; D010349:Patient Compliance; D010743:Phospholipids / Q000378:metabolism
D003692:Delayed-Action Preparations; D004042:Dietary Fats, Unsaturated; D004338:Drug Combinations; D015525:Fatty Acids, Omega-3; D005395:Fish Oils; C045153:Maxepa; D008563:Membrane Lipids; D010743:Phospholipids; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid